- Portola Pharmaceuticals (PTLA +0.9%) announces a second clinical collaboration with Bristol-Myers Squibb (BMY +1.1%) and Pfizer (PFE +0.5%) for andexanet alfa.
- The companies will now move the Factor Xa inhibitor reversal agent (i.e. antidote) into Phase 3 studies with Eliquis (expected to begin in H1).
- The deal will also "be in effect through ... any potential U.S. and EU regulatory approval."
- PTLA will get an upfront payment and is eligible for development and regulatory milestone payments, but "retains full, worldwide commercial rights to andexanet alfa." (PR)
- For reference, see here.
Portola Pharma to continue collaboration with Bristol-Myers, Pfizer
Jan 13 2014, 11:02 ET